The FDA approved an oral version of Novo Nordisk’s obesity medicine Wegovy, marking the first regulator-cleared GLP-1 pill for chronic weight management in more than a decade. The approvals signal a likely commercial ramp that could expand patient access beyond injectable formulations. Novo Nordisk has positioned the pill to capture patients seeking non-injectable options and to defend market share as competitors press into obesity therapeutics. Regulators also mirrored cardiovascular-risk reduction indications similar to the injectable form, aligning clinical utility across formulations. The development will change payer conversations and distribution channels as primary-care prescribing becomes more feasible for a widely used obesity agent. Clinicians and formulary managers will watch uptake and adherence metrics closely as a new oral GLP-1 enters routine practice.